Professor Fredrik Bäckhed has been awarded funding from SciLifeLab and the Knut and Alice Wallenberg Foundation’s joint Proof of Concept grant program. Our research team is involved in developing inhibitor drugs targeting an enzyme linked to a molecule that appears to contribute to the stiffening of the heart, liver, and other organs, which can increase the risk of heart failure and liver disease. 

At a relatively early stage, the team began working to develop potential drugs that target a bacterial enzyme, with the aim of developing a new type of drug.

“If we succeed, we should be able to offer treatment to patients with elevated levels of imidazole propionate.”

To the press release from Gothenburg University

Boost for new treatment that affects gut microbiota (akademiliv.se)

About the "Proof of Concept grant program"